SLS — Sellas Life Sciences Group Inc
NASDAQ · Healthcare · Biotechnology
$13.22
-$0.12 (-0.90%)
Sellas Life Sciences Group Inc (SLS) is a biotechnology company listed on NASDAQ. It is led by Angelos M. Stergiou M.D., ScD h.c., based in 7 Times Square, New York, NY, United States, 10036, with about 13 employees. SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Net income was -$6.8M. SLS currently screens at market cap $1.62B.
Use this SLS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SLS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SLS SEC filings page. Lician reads the product cache first so this HTML stays unique to Sellas Life Sciences Group Inc even when a live quote feed is slow.
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SLS Key Statistics
Market Cap
$1.62B
Volume
3.01M
Previous Close
$14.09
Day Range
$13.46 – $13.91
EPS
-$0.50
Revenue
$0.00
Net Income
-$30.88M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
13
SLS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.00M | $7.60M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$30.88M | -$37.34M | -$41.30M | -$20.70M |
| EPS (Diluted) | -$0.50 | -$1.34 | -$2.13 | -$1.34 |
Total Assets
$19.43M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$13.89M
Operating Cash Flow
-$35.40M
Free Cash Flow
$0.00
Sellas Life Sciences Group Inc Company Information
- Founder, President, CEO & Director
- Angelos M. Stergiou M.D., ScD h.c.
- Headquarters
- 7 Times Square, New York, NY, United States, 10036
- Website
- sellaslifesciences.com
- Phone
- 646 200 5278
- IPO / Founded
- 2017-12-29
- Sector
- Healthcare
- Industry
- Biotechnology